GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Glenn Bauman discussing a prospective provincial registry of PSMA PET/CT for recurrent prostate cancer. While most ...

Domain-specific large language model for predicting prostate cancer treatment plan. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This abstract does not include ...

The firm plans to build on its organ and tissue modeling technology to develop more sophisticated tests, including full-body digital twins.

Prime Minister Netanyahu’s doctors released a medical report detailing the procedures he has undergone and his latest blood ...

MyCareGorithm was met with high approval from patients, companions, and physicians, with all 3 groups reporting they’d ...

Data highlights PYLARIFY’s ability to detect recurrent prostate cancer in patients with low PSAReal-world evidence of PYLARIFY’s effectiveness in ...

Telix Pharmaceuticals Ltd.’s prostate cancer PET imaging agent Illuccix has been approved by the Danish Medicines Agency.

[99mTc]Tc-iPSMA SPECT/CT as an alternative to PET imaging for decision making in prostate cancer patients. PREP registry: Key findings. Total (n=4135) Cohort 1 (n=255): BF within 3 months from RP and ...